Literature DB >> 17848620

Dual ITAM-mediated proteolytic pathways for irreversible inactivation of platelet receptors: de-ITAM-izing FcgammaRIIa.

Elizabeth E Gardiner1, Denuja Karunakaran, Jane F Arthur, Fi-Tjen Mu, Maree S Powell, Ross I Baker, P Mark Hogarth, Mark L Kahn, Robert K Andrews, Michael C Berndt.   

Abstract

Collagen binding to glycoprotein VI (GPVI) induces signals critical for platelet activation in thrombosis. Both ligand-induced GPVI signaling through its coassociated Fc-receptor gamma-chain (FcRgamma) immunoreceptor tyrosine-activation motif (ITAM) and the calmodulin inhibitor, W7, dissociate calmodulin from GPVI and induce metalloproteinase-mediated GPVI ectodomain shedding. We investigated whether signaling by another ITAM-bearing receptor on platelets, FcgammaRIIa, also down-regulates GPVI expression. Agonists that signal through FcgammaRIIa, the mAbs VM58 or 14A2, potently induced GPVI shedding, inhibitable by the metalloproteinase inhibitor, GM6001. Unexpectedly, FcgammaRIIa also underwent rapid proteolysis in platelets treated with agonists for FcgammaRIIa (VM58/14A2) or GPVI/FcRgamma (the snake toxin, convulxin), generating an approximate 30-kDa fragment. Immunoprecipitation/pull-down experiments showed that FcgammaRIIa also bound calmodulin and W7 induced FcgammaRIIa cleavage. However, unlike GPVI, the approximate 30-kDa FcgammaRIIa fragment remained platelet associated, and proteolysis was unaffected by GM6001 but was inhibited by a membrane-permeable calpain inhibitor, E64d; consistent with this, micro-calpain cleaved an FcgammaRIIa tail-fusion protein at (222)Lys/(223)Ala and (230)Gly/(231)Arg, upstream of the ITAM domain. These findings suggest simultaneous activation of distinct extracellular (metalloproteinase-mediated) and intracellular (calpain-mediated) proteolytic pathways irreversibly inactivating platelet GPVI/FcRgamma and FcgammaRIIa, respectively. Activation of both pathways was observed with immunoglobulin from patients with heparin-induced thrombocytopenia (HIT), suggesting novel mechanisms for platelet dysfunction by FcgammaRIIa after immunologic insult.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17848620     DOI: 10.1182/blood-2007-04-086983

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  21 in total

1.  CLEC-2 expression is maintained on activated platelets and on platelet microparticles.

Authors:  Eelo Gitz; Alice Y Pollitt; Jerney J Gitz-Francois; Osama Alshehri; Jun Mori; Samantha Montague; Gerard B Nash; Michael R Douglas; Elizabeth E Gardiner; Robert K Andrews; Christopher D Buckley; Paul Harrison; Steve P Watson
Journal:  Blood       Date:  2014-08-22       Impact factor: 22.113

2.  Soluble GPVI is elevated in injured patients: shedding is mediated by fibrin activation of GPVI.

Authors:  Samantha J Montague; Céline Delierneux; Christelle Lecut; Nathalie Layios; Robert J Dinsdale; Christine S-M Lee; Natalie S Poulter; Robert K Andrews; Peter Hampson; Christopher M Wearn; Nathalie Maes; Jonathan Bishop; Amy Bamford; Chris Gardiner; Woei Ming Lee; Tariq Iqbal; Naiem Moiemen; Steve P Watson; Cécile Oury; Paul Harrison; Elizabeth E Gardiner
Journal:  Blood Adv       Date:  2018-02-13

3.  PRT-060318, a novel Syk inhibitor, prevents heparin-induced thrombocytopenia and thrombosis in a transgenic mouse model.

Authors:  Michael P Reilly; Uma Sinha; Pierrette André; Scott M Taylor; Yvonne Pak; Francis R Deguzman; Nisha Nanda; Anjali Pandey; Moritz Stolla; Wolfgang Bergmeier; Steven E McKenzie
Journal:  Blood       Date:  2010-11-18       Impact factor: 22.113

4.  Nerve growth factor inhibits metalloproteinase-disintegrins and blocks ectodomain shedding of platelet glycoprotein VI.

Authors:  Lakshmi C Wijeyewickrema; Elizabeth E Gardiner; Elsa L Gladigau; Michael C Berndt; Robert K Andrews
Journal:  J Biol Chem       Date:  2010-02-17       Impact factor: 5.157

5.  Receptor-independent, direct membrane binding leads to cell-surface lipid sorting and Syk kinase activation in dendritic cells.

Authors:  Gilbert Ng; Karan Sharma; Sandra M Ward; Melanie D Desrosiers; Leslie A Stephens; W Michael Schoel; Tonglei Li; Clifford A Lowell; Chang-Chun Ling; Matthias W Amrein; Yan Shi
Journal:  Immunity       Date:  2008-11-14       Impact factor: 31.745

Review 6.  Advances in the pathophysiology and treatment of heparin-induced thrombocytopenia.

Authors:  Steven E McKenzie; Bruce S Sachais
Journal:  Curr Opin Hematol       Date:  2014-09       Impact factor: 3.284

7.  Phenotypic heterogeneity in the Gray platelet syndrome extends to the expression of TREM family member, TLT-1.

Authors:  Alan T Nurden; Paquita Nurden; Emilsé Bermejo; Robert Combrié; Daniel W McVicar; A Valance Washington
Journal:  Thromb Haemost       Date:  2008-07       Impact factor: 5.249

8.  DiagnoSTic assays for heparin-induced thrombocytopenia.

Authors:  Elizabeth E Gardiner; Robert K Andrews; Adam Cuker
Journal:  Br J Haematol       Date:  2014-05-14       Impact factor: 6.998

9.  Identification of FcgammaRIIa as the ITAM-bearing receptor mediating alphaIIbbeta3 outside-in integrin signaling in human platelets.

Authors:  Brian Boylan; Cunji Gao; Vipul Rathore; Joan C Gill; Debra K Newman; Peter J Newman
Journal:  Blood       Date:  2008-07-18       Impact factor: 22.113

10.  Identity of the elusive IgM Fc receptor (FcmuR) in humans.

Authors:  Hiromi Kubagawa; Satoshi Oka; Yoshiki Kubagawa; Ikuko Torii; Eiji Takayama; Dong-Won Kang; G Larry Gartland; Luigi F Bertoli; Hiromi Mori; Hiroyuki Takatsu; Toshio Kitamura; Hiroshi Ohno; Ji-Yang Wang
Journal:  J Exp Med       Date:  2009-10-26       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.